Impacting patient-centred outcomes in COPD: Exacerbations and hospitalisations

European Respiratory Review

Volumn 15, Issue 99, 2006, Pages 47-50

  Rodriguez Roisin R ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; Exacerbations; Healthcare utilisation; Hospitalisation; Long acting anticholinergic agents

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; PLACEBO; SALMETEROL; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MORTALITY; OUTCOME ASSESSMENT; QUALITY OF LIFE; TREATMENT DURATION;

EID: 34447122732     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00009905     Document Type: Conference Paper

References (21)

1. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003; 48: 1204-1213.
2. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6. The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003; 58: 73-80.
3. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398-401.
4. Strassels SA, Smith DH, Sullivan SD, et al. The costs of treating COPD in the United States. Chest 2001; 119: 344-352.
5. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931.
6. Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698-702.
7. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
8. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2005. www.goldcopd.com. Date last accessed: September 26, 2006.
9. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
10. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209-216.
11. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.
12. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143: 317-326.
13. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27: 547-555.
14. Disse B. Antimuscarinic treatment for lung diseases from research to clinical practice. Life Sci 2001; 68: 2257-2564.
15. Koyama S, Rennard SI, Robbins RA. Acetylcholine stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Physiol 1992; 262: L466-L471.
16. Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.
17. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
18. Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21: 68-73.
19. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
20. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
21. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive disease. Eur Respir J 2003; 21: 74-81.